Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
1d agoen
From the article
Conditions : Gastric Adenocarcinoma; Gastroesophageal Junction (GEJ) Adenocarcinoma; Gastro-esophageal Junction Adenocarcinoma Interventions : Drug: Sacituzumab Tirumotecan + Fruquintinib Sponsors : Tianjin Medical University Cancer Institute and Hospital; Peking Union Medical College Hospital Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
doi.org·6d ago
Personalized Treatment Strategies for HER2-Positive Gastroesophageal Adenocarcinoma
This article discusses evolving strategies for personalized treatment of HER2-positive gastroesophageal adenocarcinoma (GEA). It features in
mdsc.pe·19d ago
Avacta Therapeutics presents platform-validating data for faridoxorubicin in salivary gland cancer at BIO International Conference
Avacta Therapeutics announced platform-validating clinical data for faridoxorubicin (AVA6000), a tumor-activated oncology drug using its pre
avacta.com·13d ago
Combination therapy with RAS inhibitors shows promise for pancreatic cancer regression and resistance prevention
This research article presents a study on a targeted combination therapy for pancreatic ductal adenocarcinoma (PDAC), one of the deadliest c
pnas.org·28d agoReal-World EV Plus Pembro Success Seen in Urothelial Cancer
Medscape·20h ago
SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial
doi.org·6d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.